Topical Testosterone Therapy Adherence and Outcomes Among Men With Primary or Secondary Hypogonadism
- PMID: 29425664
- DOI: 10.1016/j.jsxm.2017.11.225
Topical Testosterone Therapy Adherence and Outcomes Among Men With Primary or Secondary Hypogonadism
Erratum in
-
Erratum.J Sex Med. 2018 Jul;15(7):1063. doi: 10.1016/j.jsxm.2018.05.013. J Sex Med. 2018. PMID: 29960628 No abstract available.
Abstract
Background: Men with primary or secondary hypogonadism (HG) prescribed testosterone therapy (TTh) who terminate treatment early might not obtain the benefit of symptom relief.
Aim: To estimate adherence to topical TTh and to compare baseline characteristics and follow-up outcomes between adherent and non-adherent patients in a population of commercially insured US men with primary or secondary HG.
Methods: A retrospective cohort of adult men with primary or secondary HG and initiating topical TTh from 2007 through 2014, with continuous coverage during 12-month baseline and follow-up periods, was identified from a large US health plan. Clinical conditions were assessed using International Classification of Diseases, 9th Revision, Clinical Modification codes. Adherence to initial topical TTh was defined as proportion of days covered of at least 80%. Characteristics and outcomes were compared across adherent and non-adherent patients.
Outcomes: Adherence to topical TTh, occurrence of HG-related clinical outcomes, and total health care costs.
Results: We identified 3,184 topical TTh initiators (mean age = 49 years), of whom 17% (n = 538) were adherent at 12 months. Factors positively associated with adherence included prescribing by specialists, a lower prevalence of certain comorbidities at baseline, residence in the Northeast, and an earlier start year of the topical TTh prescription. Adherence to topical TTh was associated with lower odds of having HG-associated clinical conditions (composite measure) over 12-month follow-up. In the subset of patients with available laboratory results, adherent patients had greater increases in testosterone levels compared with non-adherent patients. Increased pharmacy costs for adherent patients were partly offset by decreases in medical costs.
Clinical implications: Adherence to topical testosterone is low but associated with positive outcomes, demonstrating the need for future efforts to focus on improving adherence in this population.
Strengths and limitations: Strengths of this study include the large number of analyzed patients and the routine care (rather than interventional trial) setting, which maximizes generalizability within the source population. Limitations are primarily a result of reliance on medical claims data, which lack clinical context and are subject to potential coding errors. Certain factors of potential importance for adherence, such as patient and provider preferences, were not available in the dataset. The study analyzed commercially insured US patients and our ability to generalize these results to the entire US population or other countries might be limited.
Conclusion: Study findings provide further evidence for suboptimal topical TTh adherence among men treated for primary or secondary HG. Adherence is associated with greater improvement in total testosterone laboratory values and might be associated with a lower likelihood of having certain HG-related conditions. Grabner M, Hepp Z, Raval A, et al. Topical Testosterone Therapy Adherence and Outcomes Among Men With Primary or Secondary Hypogonadism. J Sex Med 2018;15:148-158.
Keywords: Hypogonadism; Medication Adherence; Retrospective Studies; Testosterone.
Copyright © 2017 The Authors. Published by Elsevier Inc. All rights reserved.
Similar articles
-
Clinical Characteristics, Health Care Utilization and Costs Among Men with Primary or Secondary Hypogonadism in a US Commercially Insured Population.J Sex Med. 2017 Jan;14(1):88-97. doi: 10.1016/j.jsxm.2016.10.012. Epub 2016 Dec 8. J Sex Med. 2017. PMID: 27939338
-
Trends in Testosterone Therapy use in Prostate Cancer Survivors in the United States.J Sex Med. 2021 Aug;18(8):1346-1353. doi: 10.1016/j.jsxm.2021.06.007. Epub 2021 Jul 22. J Sex Med. 2021. PMID: 34303630 Free PMC article.
-
Medication adherence and treatment patterns for hypogonadal patients treated with topical testosterone therapy: a retrospective medical claims analysis.J Sex Med. 2013 May;10(5):1401-9. doi: 10.1111/jsm.12114. Epub 2013 Mar 6. J Sex Med. 2013. PMID: 23464534
-
Testosterone Therapy and Cardiovascular Risk: A Critical Analysis of Studies Reporting Increased Risk.J Sex Med. 2021 Jan;18(1):83-98. doi: 10.1016/j.jsxm.2020.10.019. Epub 2020 Dec 11. J Sex Med. 2021. PMID: 33317996 Review.
-
Cardiovascular Morbidity and Mortality in Men - Findings From a Meta-analysis on the Time-related Measure of Risk of Exogenous Testosterone.J Sex Med. 2022 Aug;19(8):1243-1254. doi: 10.1016/j.jsxm.2022.05.145. Epub 2022 Jun 23. J Sex Med. 2022. PMID: 35753891 Review.
Cited by
-
Association of Male Hypogonadism With Risk of Hospitalization for COVID-19.JAMA Netw Open. 2022 Sep 1;5(9):e2229747. doi: 10.1001/jamanetworkopen.2022.29747. JAMA Netw Open. 2022. PMID: 36053534 Free PMC article.
-
Impact of Testosterone on Alzheimer's Disease.World J Mens Health. 2022 Apr;40(2):243-256. doi: 10.5534/wjmh.210175. Epub 2022 Jan 2. World J Mens Health. 2022. PMID: 35021306 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources